Mark Hartman
Company: Eli Lilly & Co.
Job title: Vice President, Medical, NASH/Obesity
Seminars:
Chair’s Closing Remarks 2:30 pm
day: Seminar A- PM tracks
The Power of Three G’s: Retatrutide Phase 2 Results in Participants with T2DM, Obesity & NAFLD 9:30 am
Delving into Retatrutide (LY3437943): a triple agonist of the GIP, GLP-1 and glucagon receptors to better understand its mechanism of action Showing clinically meaningful improvements in glycemic control and robust reductions in body weight in a Phase 2 study in participants with T2DM Demonstrating substantial reductions in body weight in a Phase 2 study in…Read more
day: Seminar A- AM tracks
Chair’s Opening Remarks 9:25 am
day: Seminar A- AM tracks
Entering a New Era: Discovering New Targets with Potential to Alter Disease Evolution
Seminar Moderator: 9:24 am
Seminar Moderator:
day: Seminar A- AM tracks